


N 85650-52-8 REGISTRY
 CN Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, (.+-.)-
 OTHER NAMES:
 CN ~~6-Azamianserin~~
 CN Mepirzapin
 CN Mepirzepine
 CN ~~Mirtazapine~~
 CN Mirtazepine
 CN Mirtazipine
 CN Org 3770
 CN Promyrtil
 CN Remergil
 CN Remergon
 CN Remeron
 CN Rexer
 CN Zispin
 FS 3D CONCORD
 DR 61337-67-5, 82601-27-2
 MF C17 H19 N3
 CI COM
 SR Commission of European Communities
 LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PIRA, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

289 REFERENCES IN FILE CA (1957 TO DATE)
 7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 289 REFERENCES IN FILE CAPLUS (1957 TO DATE)

=> file medicine

ACCESSION NUMBER: 158818 EMBASE
DOCUMENT NUMBER: 1996158818
TITLE: Mirtazapine. A review of its pharmacology and therapeutic potential in the management of major depression.
AUTHOR: Davis R.; Wilde M.I.
CORPORATE SOURCE: Adis International Limited, 41 Centorian Drive, Mairangi Bay, Auckland 10, New Zealand
SOURCE: CNS Drugs, (1996) 5/5 (389-402).
ISSN: 1172-7047 CODEN: CNDREF
COUNTRY: New Zealand
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 032 Psychiatry
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English

AB Mirtazapine is a tetracyclic antidepressant with a novel mechanism of action; it increases noradrenergic and serotonergic neurotransmission via blockade of central α_2 -adrenergic auto- and heteroreceptors. The increased release of serotonin (5-hydroxytryptamine; 5-HT) stimulates serotonin 5-HT₁ receptors because mirtazapine directly blocks 5-HT₂ and 5-HT₃ receptors. The enhancement of both noradrenergic- and 5-HT₁ receptor-mediated neurotransmission is thought to be responsible for the antidepressant activity of mirtazapine. In short term (5 to 6 weeks) clinical trials in patients with depression, mirtazapine produces clinical improvements significantly superior to those of placebo, similar to those of tricyclic antidepressants (TCAs) [amitriptyline, clomipramine and doxepin] and possibly superior to those of trazodone. Short term clinical tolerability data suggest that mirtazapine produces fewer anticholinergic-, adrenergic- and serotonergic-related adverse events than TCAs. In rare cases, mirtazapine, in common with many antidepressants, was associated with potentially serious changes in haematological parameters (e.g. agranulocytosis and neutropenia). The drug appears to be safe in overdose and possesses a very low propensity for inducing seizures. Comparisons with other classes of antidepressants are needed to determine the relative position of mirtazapine in clinical practice. However, preliminary data indicate that mirtazapine, with its novel mechanism of

action, is a promising addition to currently available options for the treatment of depression.

file

ACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE:

1998:426105 HCAPLUS
129:225564

Characterization of enhanced behavioral responses to
L-DOPA following repeated administration in the
6-hydroxydopamine-lesioned rat model of
Parkinson's disease

AUTHOR(S):
CORPORATE SOURCE:

Henry, Brian; Crossman, Alan R.; Brotchie, Jonathan M.
Manchester Movement Disorder Laboratory, Division of
Neuroscience, School of Biological Sciences,
University of Manchester, Manchester, M13 9PT, UK
Experimental Neurology (1998), 151(2), 334-342
CODEN: EXNEAC; ISSN: 0014-4886

SOURCE:

PUBLISHER:
DOCUMENT TYPE:
LANGUAGE:

Academic Press
Journal
English

AB Long-term treatment of **Parkinson's disease** with dopamine-replacing agents such as L-3,4-dihydroxy-phenylalanine (L-DOPA) is compromised by many side-effects, most notably involuntary movements, L-DOPA-induced dyskinesia. Acute challenge with dopamine-replacing drugs elicits a rotational response in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of **Parkinson's disease**. This rotation is contraversive to the lesion and is considered to represent an antiparkinsonian effect. More recently, it has become clear that the rotational response shows plasticity and that repeated L-DOPA or apomorphine therapy is accompanied by a marked enhancement in this response. In this study, the authors demonstrate that the enhanced behavioral response to repeated dopamine-replacement therapy seen in the 6-OHDA-lesioned rat has pharmacol. characteristics similar to L-DOPA-induced dyskinesia seen in MPTP-lesioned primates and man. Thus, the magnitude and rate of development of the enhanced response to L-DOPA treatment is related to both the no. of doses and the size of the dose of L-DOPA administered. In contrast, de novo administration of dopaminergic drugs that are assocd. with a lower incidence of dyskinesia, e.g., bromocriptine or lisuride, does not lead to an enhanced behavioral response following repeated treatment. However, following a single "priming" administration of apomorphine, the rotational response elicited by subsequent bromocriptine administrations is enhanced with repeated treatment. Once established, the enhanced behavioral response to repeated L-DOPA-administration (6.5 mg/kg, twice daily) can, like L-DOPA-induced dyskinesia in man and MPTP-treated monkeys, be selectively reduced by coadministration of L-DOPA with the **alpha2**-adrenergic receptor antagonist yohimbine (10 mg/kg, -95%), the 5-HT

uptake inhibitor 6-MDOT (2 mg/kg, -90%); or the α -adrenergic receptor antagonist propranolol (10 mg/kg, -35%). While these rats do not exhibit symptoms of dyskinesia per se, this rodent model does exhibit behaviors, the underlying mechanism of which is likely to be similar to that underlying L-DOPA-induced dyskinesia and may prove useful in studying the mol. and cellular mechanisms of L-DOPA-induced dyskinesia in Parkinson's disease.. (c) 1998 Academic Press.

CC 1-11 (Pharmacology)

ST behavior sensitization DOPA parkinsonism dyskinesia;

dopaminergic drug behavior sensitization parkinsonism dyskinesia

IT Antiparkinsonian agents

Dopamine agonists

(characterization of enhanced behavioral responses to L-DOPA and other dopaminergic drugs following repeated administration in hydroxydopamine-lesioned rat model of Parkinson's disease in relation to induction of dyskinesia)

IT Toxicity

(drug; characterization of enhanced behavioral responses to L-DOPA and other dopaminergic drugs following repeated administration in hydroxydopamine-lesioned rat model of Parkinson's disease in relation to induction of dyskinesia)

IT Nervous system

(dyskinesia; characterization of enhanced behavioral responses to L-DOPA and other dopaminergic drugs following repeated administration in hydroxydopamine-lesioned rat model of Parkinson's disease in relation to induction of dyskinesia)

IT Behavior

(rotational; characterization of enhanced behavioral responses to L-DOPA and other dopaminergic drugs following repeated administration in hydroxydopamine-lesioned rat model of Parkinson's disease in relation to induction of dyskinesia)

IT Behavior

(sensitization; characterization of enhanced behavioral responses to L-DOPA and other dopaminergic drugs following repeated administration in hydroxydopamine-lesioned rat model of Parkinson's disease in relation to induction of dyskinesia)

IT 58-00-4, Apomorphine 7101-51-1, L-DOPA methyl ester 19875-60-6
25614-03-3, Bromocriptine

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses).

(characterization of enhanced behavioral responses to L-DOPA and other dopaminergic drugs following repeated administration in hydroxydopamine-lesioned rat model of Parkinson's disease in relation to induction of dyskinesia)

REFERENCE COUNT:

40

THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1991:74612 HCAPLUS
DOCUMENT NUMBER: 114:74612
TITLE: A novel in vivo test for drugs affecting central
serotonergic and adrenergic systems
AUTHOR(S): Rawlow, Andrew; King, Roger G.
CORPORATE SOURCE: Dep. Pharmacol., Monash Univ., Clayton, 3168,
Australia
SOURCE: European Journal of Pharmacology (1990), 191(3),
263-72
CODEN: EJPHAZ; ISSN: 0014-2999
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In urethane anesthetized rats, **myoclonic** twitches of the anterior digastricus muscle were evoked by L-5-hydroxytryptophan (L-5-HTP, 50-100 mg/kg i.v.), the serotonin (5-HT) receptor agonist, quipazine (1-8 mg/kg i.v.) and the 5-HT releaser, fenfluramine (4-8 mg/kg i.v.). The effect of L-5-HTP or quipazine on the frequency of twitches was **inhibited** by the 5-HT receptor **antagonist** cyproheptadine. Also L-DOPA (100 mg/kg i.p.) or the .alpha.1-adrenoceptor agonist, cirazoline (0.3-3 mg/kg i.v.) evoked twitches of the muscle which were inhibited by the .alpha.1-adrenoceptor antagonist, prazosin. In decerebrate, artificially respired rats, neither L-5-HTP nor L-DOPA evoked the twitches. The frequency of twitches evoked by fenfluramine but not by L-DOPA was increased by the .alpha.2-adrenoceptor agonist, clonidine (0.2 and 0.4 mg/kg i.v.); clonidine's effect was abolished by the .alpha.2-adrenoceptor **antagonist**, yohimbine. The .beta.2-adrenoceptor agonist, salbutamol (0.01-1 mg/kg i.v.) had no effect on fenfluramine-induced twitches. It is concluded that (1) activation of 5-HT receptors or .alpha.1-adrenoceptors in the brain of urethane-anesthetized rats evokes twitches of the anterior digastricus muscle, and (2) this prepn. can be utilized as a test to study the action of compds. on central 5-HT and adrenergic systems.

CC 1-1 (Pharmacology)